Organon & Co.: Schizophrenia trials

The registry lists 21 Schizophrenia studies with Organon & Co. as lead sponsor. 0 are open to participants now and 13 have results posted.

Phase 1 1Phase 2 1Phase 3 18No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)CompletedNCT01617187Phase 3Results posted
• Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)CompletedNCT01244828Phase 3Results posted
• A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1)CompletedNCT01206517Phase 1Results posted
• Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897)CompletedNCT01190267Phase 3Results posted
• Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)CompletedNCT01190254Phase 3Results posted
• Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P06125)CompletedNCT01142596Phase 3Results posted
• A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937)CompletedNCT01101464Phase 2Results posted
• 6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124)CompletedNCT01098110Phase 3Results posted
• 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)CompletedNCT00265343Phase 3Results posted
• 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)CompletedNCT00174265Phase 3Results posted
• Long-Term Efficacy and Safety of Asenapine Using Haloperidol as a Positive Control (41513)(COMPLETED)(P05785)CompletedNCT00156065Phase 3Results posted
• To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)CompletedNCT00150176Phase 3Results posted
• Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (A7501013)(COMPLETED)(P05771)CompletedNCT00145496Phase 3Results posted
• Post-Authorization Safety Surveillance Study of Asenapine in Participants With Bipolar Disorder (P08307)CompletedNCT01495741
• Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817)CompletedNCT00212836Phase 3
• Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)CompletedNCT00212784Phase 3
• Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846)CompletedNCT00212771Phase 3
• Efficacy and Safety of Asenapine With Placebo and Olanzapine (41021)(P05933)CompletedNCT00156117Phase 3
• Efficacy and Safety of Asenapine With Placebo and Haloperidol (41023)(P05926)(COMPLETED)CompletedNCT00156104Phase 3
• Long-Term Efficacy and Safety of Asenapine Using Olanzapine as a Positive Control (41512)(COMPLETED)(P05784)CompletedNCT00156091Phase 3
• Efficacy and Safety of Asenapine With Placebo and Olanzapine (41022)(P05947)CompletedNCT00151424Phase 3